Begins Coverage on Ekso Bionics (NASDAQ:EKSO) assumed coverage on shares of Ekso Bionics (NASDAQ:EKSOGet Rating) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright lowered their target price on shares of Ekso Bionics from $11.00 to $9.00 and set a buy rating on the stock in a research report on Friday, July 29th.

Ekso Bionics Trading Down 4.1 %

Shares of NASDAQ:EKSO opened at $1.18 on Monday. Ekso Bionics has a 1 year low of $1.18 and a 1 year high of $3.54. The business has a fifty day simple moving average of $1.50 and a 200 day simple moving average of $1.79. The firm has a market cap of $15.51 million, a price-to-earnings ratio of -1.03 and a beta of 1.85.

Hedge Funds Weigh In On Ekso Bionics

Hedge funds have recently bought and sold shares of the business. Essex Investment Management Co. LLC acquired a new stake in shares of Ekso Bionics in the first quarter valued at about $484,000. Renaissance Technologies LLC grew its position in shares of Ekso Bionics by 153.4% in the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after purchasing an additional 27,006 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Ekso Bionics in the third quarter valued at about $28,000. 12.47% of the stock is owned by institutional investors and hedge funds.

About Ekso Bionics

(Get Rating)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Read More

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with's FREE daily email newsletter.